Moracizine

Moracizine

Moracizine is a Class I antiarrhythmic agent that was developed for the treatment of arrhythmia. It is a phenothiazine derivative and is classified as a Class IC antiarrhythmic drug according to the Vaughan Williams classification system.

Pharmacology

Moracizine works by blocking the fast inward sodium current, thereby slowing the rate of rise of the action potential, Phase 0. It has a high affinity for the inactivated state of the sodium channel, and has little effect on the resting state. This results in a decrease in the excitability and conduction velocity of the heart tissue, which can help to restore normal rhythm.

Clinical Use

Moracizine was primarily used for the treatment of ventricular tachycardia and symptomatic ventricular premature beats. However, it was withdrawn from the market due to concerns about its safety and efficacy.

Side Effects

The most common side effects of Moracizine include dizziness, blurred vision, and gastrointestinal disturbances. More serious side effects can include cardiotoxicity, which can lead to life-threatening arrhythmias.

History

Moracizine was first synthesized in the 1970s and was marketed under the brand name Ethmozine. However, it was withdrawn from the market in the early 2000s due to concerns about its safety and efficacy.

See Also

• Antiarrhythmic agent
• Vaughan Williams classification
• Cardiotoxicity

List of antiarrhythmic agents:

• Amiodarone
• Disopyramide
• Dofetilide
• Dronedarone
• Flecainide
• Ivabradine
• Mexiletine
• Procainamide
• Propafenone
• Quinidine

‎